These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 16291489)

  • 21. Motivations for using misoprostol for abortion outside the formal healthcare system in Colombia: a qualitative study of women seeking postabortion care in Bogotá and the Coffee Axis.
    Ortiz J; Blades N; Prada E
    Reprod Health; 2024 Jun; 21(1):76. PubMed ID: 38824533
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Misoprostol alone for early medical abortion in a Latin American clinic setting.
    Billings DL
    Reprod Health Matters; 2004 Nov; 12(24 Suppl):57-64. PubMed ID: 15938158
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Medical abortion in rural Tamil Nadu, South India: a quiet transformation.
    Ramachandar L; Pelto PJ
    Reprod Health Matters; 2005 Nov; 13(26):54-64. PubMed ID: 16291486
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Female genital mutilation in the context of migration: experience of African women with the Swiss health care system.
    Thierfelder C; Tanner M; Bodiang CM
    Eur J Public Health; 2005 Feb; 15(1):86-90. PubMed ID: 15788809
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Complications with use of misoprostol for abortion in Madagascar: between ease of access and lack of information.
    Pourette D; Mattern C; Ratovoson R; Raharimalala P
    Contraception; 2018 Feb; 97(2):116-121. PubMed ID: 29242087
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increasing women's choices in medical abortion: a study of misoprostol 400 microg swallowed immediately or held sublingually following 200 mg mifepristone.
    Akin A; Dabash R; Dilbaz B; Aktün H; Dursun P; Kiran S; Aksan G; Doğan B; Winikoff B
    Eur J Contracept Reprod Health Care; 2009 Jun; 14(3):169-75. PubMed ID: 19565414
    [TBL] [Abstract][Full Text] [Related]  

  • 27. One or two day mifepristone-misoprostol interval for second trimester abortion.
    Nilas L; Glavind-Kristensen M; Vejborg T; Knudsen UB
    Acta Obstet Gynecol Scand; 2007; 86(9):1117-21. PubMed ID: 17712654
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Women use illicit drug to induce abortion.
    Indian Med Trib; 1993 Sep; 1(6):11. PubMed ID: 12179168
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mifepristone- and misoprostol-induced mid-trimester termination of pregnancy: a review of 272 cases.
    Rose SB; Shand C; Simmons A
    Aust N Z J Obstet Gynaecol; 2006 Dec; 46(6):479-85. PubMed ID: 17116051
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Beyond the law: Misoprostol and medical abortion in Dar es Salaam, Tanzania.
    Solheim IH; Moland KM; Kahabuka C; Pembe AB; Blystad A
    Soc Sci Med; 2020 Jan; 245():112676. PubMed ID: 31810016
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Why are women still aborting outside designated facilities in metropolitan South Africa?
    Jewkes RK; Gumede T; Westaway MS; Dickson K; Brown H; Rees H
    BJOG; 2005 Sep; 112(9):1236-42. PubMed ID: 16101602
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hidden realities: What women do when they want to terminate an unwanted pregnancy in Bolivia.
    Bury L; Aliaga Bruch S; Machicao Barbery X; Garcia Pimentel F
    Int J Gynaecol Obstet; 2012 Sep; 118 Suppl 1():S4-9. PubMed ID: 22840269
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Termination of early pregnancy using flexible, low-dose mifepristone-misoprostol regimens.
    Heikinheimo O; Leminen R; Suhonen S
    Contraception; 2007 Dec; 76(6):456-60. PubMed ID: 18061704
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is misoprostol a safe, effective and acceptable alternative to manual vacuum aspiration for postabortion care? Results from a randomised trial in Burkina Faso, West Africa.
    Dao B; Blum J; Thieba B; Raghavan S; Ouedraego M; Lankoande J; Winikoff B
    BJOG; 2007 Nov; 114(11):1368-75. PubMed ID: 17803715
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Misoprostol for termination of mid-trimester post-Caesarean pregnancy.
    Bhattacharjee N; Ganguly RP; Saha SP
    Aust N Z J Obstet Gynaecol; 2007 Feb; 47(1):23-5. PubMed ID: 17261095
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Determinants of abortion among women admitted to hospitals in Fortaleza, North Eastern Brazil.
    Misago C; Fonseca W; Correia L; Fernandes LM; Campbell O
    Int J Epidemiol; 1998 Oct; 27(5):833-9. PubMed ID: 9839740
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Provision of harm-reduction services to limit unsafe abortion in Tanzania.
    Kahabuka C; Pembe A; Meglioli A
    Int J Gynaecol Obstet; 2017 Feb; 136(2):210-214. PubMed ID: 28099731
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Latin American women's experiences with medical abortion in settings where abortion is legally restricted.
    Zamberlin N; Romero M; Ramos S
    Reprod Health; 2012 Dec; 9(1):34. PubMed ID: 23259660
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mifepristone followed in 24 hours to 48 hours by misoprostol for late first-trimester abortion.
    Bracken H; Ngoc NT; Schaff E; Coyaji K; Ambardekar S; Westheimer E; Winikoff B
    Obstet Gynecol; 2007 Apr; 109(4):895-901. PubMed ID: 17400851
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Facilitating women's access to misoprostol through community-based advocacy in Kenya and Tanzania.
    Coeytaux F; Hessini L; Ejano N; Obbuyi A; Oguttu M; Osur J; Shuken K
    Int J Gynaecol Obstet; 2014 Apr; 125(1):53-5. PubMed ID: 24447412
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.